Collegium Pharmaceutical reported third quarter 2026 financial results and reaffirmed its 2026 guidance. The company’s Q3 earnings and revenues exceeded expectations according to multiple news reports. Earnings call transcripts and highlights provide detailed insights into operational performance and key metrics. Prior to the quarter, earnings previews anticipated a decline, but the actual results showed strength. The company continues to navigate a complex regulatory environment and competitive landscape.

• Collegium reported third quarter 2026 financial results and reaffirmed 2026 guidance [N2].
• The company’s Q3 2026 earnings and revenues topped estimates according to multiple news articles [N5][N6].
• Earnings call transcripts and highlights from Q3 2026 provide detailed operational insights [N3][N4].
• Prior to Q3 results, earnings previews anticipated a decline in earnings [N7].
• The company continues to operate within a challenging regulatory environment for opioid products [N2].

Collegium’s portfolio includes unique products such as Jornay PM for ADHD and abuse-deterrent opioids like Xtampza ER, supported by proprietary technology and pediatric exclusivities. The company’s dedicated sales forces and market-access teams focus on educating prescribers and securing formulary coverage. Recent reaffirmation of 2026 guidance and positive net income demonstrate operational execution. Continued monitoring and compliance with regulatory requirements support sustained commercialization.

The company faces substantial indebtedness that may constrain financial flexibility. Regulatory risks include potential changes to FDA labeling, opioid prescribing guidelines, and REMS requirements that could impact product sales. Dependence on third-party manufacturers and sole suppliers for active pharmaceutical ingredients introduces supply risks. Generic competition for Nucynta IR and ER products may pressure revenues. Litigation and intellectual property challenges could affect commercialization.

Collegium’s moat derives from its portfolio of FDA-approved, differentiated pharmaceutical products with abuse-deterrent formulations and pediatric exclusivities, proprietary manufacturing processes (notably for Xtampza ER), and established commercial infrastructure targeting specialized prescriber segments in ADHD and pain management. The company’s abuse-deterrent technology and regulatory approvals provide barriers to entry. However, the presence of generic competition for some products and regulatory scrutiny of opioids present ongoing challenges.

• Substantial Indebtedness: Collegium has significant outstanding debt including an $854.5 million term loan and $241.5 million in convertible notes, which may limit financial flexibility and increase vulnerability to economic downturns [S2].
• Regulatory and Legal Risks: The company’s opioid products are subject to extensive FDA regulation, including abuse-deterrent labeling and REMS programs. Changes in regulatory requirements or unfavorable FDA actions could adversely affect commercialization [S1][S2].
• Dependence on Third-Party Manufacturers and Suppliers: Manufacturing and supply of active pharmaceutical ingredients rely on third parties and limited suppliers, posing risks of production disruptions [S1][S2].
• Competition and Generic Entry: Generic versions of Nucynta IR have launched, and generic competition for Nucynta ER is anticipated, which may reduce market share and revenues [S1].
• Intellectual Property Challenges: The company faces risks related to patent litigation and maintaining intellectual property rights, which could impact its ability to commercialize products [S2].

• Collegium Pharmaceutical, Inc is a biopharmaceutical company focused on developing, licensing, and acquiring differentiated products for treatment of ADHD and moderate to severe pain in the United States [S1].
• The company commercializes products including Jornay PM (ADHD stimulant), Belbuca (buccal film opioid), Xtampza ER (abuse-deterrent extended-release oxycodone), Nucynta ER and IR (tapentadol opioids), and Symproic (treatment for opioid-induced constipation) [S1].
• Jornay PM is the only FDA-approved evening-dosed stimulant for ADHD, acquired via Ironshore acquisition in 2024, expanding Collegium into neuropsychiatry [S1].
• Xtampza ER uses proprietary DETERx abuse-deterrent technology designed to resist tampering and dose dumping; real-world abuse data shows low abuse compared to other Schedule II opioids [S1].
• The Nucynta Products have FDA pediatric exclusivity extensions through early 2027 and are subject to authorized generic agreements and generic competition starting in early 2026 [S1].
• Symproic is FDA-approved for opioid-induced constipation in adults with chronic non-cancer pain [S1].
• The company markets its products in the US through two dedicated sales forces: approximately 105 reps for pain products and 200 reps for ADHD products, targeting key prescribers [S1].
• Manufacturing is outsourced to third-party manufacturers with proprietary processes for Xtampza ER; supply agreements cover all products [S1].
• The company’s products contain controlled substances classified as Schedule II or III, subject to extensive regulation [S1].
• As of September 30, 2026, Collegium had $144.8 million in cash and equivalents, current assets of $611.8 million, current liabilities of $603.1 million, a current ratio of 1.01, and a cash ratio of 0.24 [S2].
• Net income for the quarter ending September 30, 2026 was $21.8 million with basic EPS of $0.69 and diluted EPS of $0.60 [S2].
• Collegium reaffirmed its 2026 guidance in its third quarter 2026 financial results announcement [N2].
• Recent news coverage includes detailed Q3 2026 earnings reports, earnings call transcripts, and analysis of key metrics [N2][N3][N4][N5][N6].
• The company faces risks including substantial indebtedness ($854.5 million term loan and $241.5 million convertible notes), regulatory and litigation risks related to opioid products, competition, and dependence on third-party manufacturers and suppliers [S2].
• Regulatory environment includes FDA abuse-deterrent labeling requirements, REMS programs, and evolving opioid prescribing guidelines [S1][S2].
• The company’s ability to maintain profitability depends on successful commercialization, manufacturing, sales execution, intellectual property protection, and regulatory compliance [S2].
• The company’s products address significant markets: ADHD affects millions of children and adults in the US; chronic pain affects approximately 24.3% of US adults with high economic costs [S1].
• The company monitors real-world abuse data and complies with FDA labeling and safety requirements, including recent opioid safety labeling changes [S1][S2].